Cargando…

Antibody-drug conjugates: the clinical development in gastric cancer

Gastric cancer (GC) is a prevalent malignant tumor of the digestive system worldwide, ranking among the top five in terms of incidence and mortality. However, the clinical efficacy of conventional treatments for gastric cancer remains limited, with a median overall survival of approximately eight mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yingze, Zhou, Miao, Kong, Wenyue, Li, Congling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250015/ https://www.ncbi.nlm.nih.gov/pubmed/37305567 http://dx.doi.org/10.3389/fonc.2023.1211947

Ejemplares similares

Platelet count and gastric cancer susceptibility: A Mendelian randomization study
por: Zhu, Yingze, et al.
Publicado: (2023)

Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022)

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021)

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis
por: Yao, Peizhuo, et al.
Publicado: (2023)

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
por: Jin, Yangbing, et al.
Publicado: (2021)

Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
por: Fenton, Sarah E., et al.
Publicado: (2023)

Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data
por: Cui, Yishuang, et al.
Publicado: (2023)

Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism?
por: Marcucci, Fabrizio, et al.
Publicado: (2019)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
por: Yu, Minghui, et al.
Publicado: (2023)

M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection
por: Hu, Jianwen, et al.
Publicado: (2021)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

New Advances in Nano-Drug Delivery Systems: Helicobacter pylori and Gastric Cancer
por: Zhu, Xiang, et al.
Publicado: (2022)

Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance
por: Liu, Ying, et al.
Publicado: (2022)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Bioprocess development of antibody-drug conjugate production for cancer treatment
por: Ou, Jianfa, et al.
Publicado: (2018)

Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer
por: Jia, Xiya, et al.
Publicado: (2022)

Book Review: Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer
por: Dhakal, Dipesh, et al.
Publicado: (2017)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs
por: Liu, Yao, et al.
Publicado: (2022)

A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma
por: Rather, Gulam M., et al.
Publicado: (2019)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Circular RNA Circ-0002570 Accelerates Cancer Progression by Regulating VCAN via MiR-587 in Gastric Cancer
por: Yang, Lei, et al.
Publicado: (2021)

Development and Validation of an Immune-Related Signature for the Prediction of Recurrence Risk of Patients With Laryngeal Cancer
por: Zhang, Hang, et al.
Publicado: (2021)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer
por: Yang, Yan, et al.
Publicado: (2023)

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs, volume II
por: Yan, Miao, et al.
Publicado: (2023)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma
por: Zhu, Bing, et al.
Publicado: (2023)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Developing and validating nomograms for predicting the survival in patients with clinical local-advanced gastric cancer
por: Hou, Chong, et al.
Publicado: (2022)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Exploration of the antibody–drug conjugate clinical landscape
por: Maecker, Heather, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rctfk7ghmgdme49ish4to1qb0p